01 nov
|
FORESEE
|
Valencia
Valencia, Spain Call4Entrepreneurs - The Collider
About the job CEO AUMMIS (The Collider Programme) CEO AUMMIS (The Collider Programme)
AUMMIS | Stem-free Uterine Manipulator for Minimally Invasive Surgery
CEO & Co-Founder Opportunity |
MedTech | Gynecologic Oncology
Laparoscopic hysterectomy depends on a uterine manipulator, and almost every model on the market works by inserting a rigid stem into the uterus. Clinical evidence has linked these manipulators to a higher risk of
cancer recurrence , because the stem damages tissue, manipulates the tumor and can spread malignant cells. As a result, many oncology patients still undergo open surgery.
AUMMIS
removes the stem. Its
vacuum-assisted system
holds the cervix with interchangeable cups, so surgeons can mobilize the uterus in laparoscopic and robotic surgery without traumatizing tissue or touching the tumor. The project was born at
FISABIO
and
Universitat Jaume I , and is now looking for the CEO who will turn it into a company.
Where AUMMIS stands today
Functional prototype , with proof of concept completed on cadaveric bodies ( TRL 4 ) Granted Spanish patent , with
EPO and US
applications pending and
freedom to operate
confirmed in Europe and the US Classified as a
Class IIa medical device ~1.3 million hysterectomies
performed worldwide every year A market dominated by
large surgical device players
whose manipulators are mostly stem-based, a clear path to
licensing or strategic partnership A defined roadmap to
CE marking , with
pilot clinical studies planned for 2027
and a financial strategy combining non-dilutive funding and private investment €143K grant from the Valencian Innovation Agency (AVI) , co-funded by the EU (ERDF), to advance development, validation and transfer of the device
The founding team
Dr. J. Antonio Llueca Abella
– Future CSO. A gynecologic oncology surgeon and Principal Clinical Investigator at FISABIO, he identified the problem in the operating room.
By the end of the 4-month validation phase, you will have:
A defined
business model and partnering strategy : licensing, co-development or a path to direct sales A
regulatory and clinical roadmap
under MDR, toward CE marking and FDA A
funding plan for the next 24 months , combining non-dilutive programmes and private investment First conversations opened with
medical device manufacturers and distributors Agreement with the founding team on the
company structure
and spin-off creation
The Offer
Significant co-founder equity stake
as CEO upon company incorporation €8,000 stipend
during the validation phase (4 monthly instalments of €2,000) Opportunity to access a
participative loan of up to €75,000
to finance the first phases of the project The Collider venture-building programme : mentors and specialists in medtech, IP, regulatory, go-to-market and fundraising, plus support with spin-off creation International exposure
through The Collider ecosystem (4YFN, Mobile World Congress, corporate & investor networks) Two years of post-incorporation support , including in-kind services, community access and portfolio perks Expected start:
February-March 2027
What you bring
Previous founder or early-stage startup experience Proven track record in the medical device industry , in BD, product, regulatory or general management, ideally with surgical devices or disposables Hands-on experience moving a device through MDR/CE
or running clinical studies. You know what it takes to go from prototype to first-in-human. A network in the medtech industry : manufacturers, distributors or strategic partners Experience closing deals , such as licensing, partnerships or fundraising, including non-dilutive funding (EU, CDTI or similar) Ability to translate clinical evidence into a business case
that convinces partners, investors and regulators, working closely with surgeons and engineers Eligible to work in Spain
and fluent in
Spanish and English Background in gynecology, oncology or minimally invasive and robotic surgery
#J-18808-Ljbffr
📌 CEO AUMMIS (The Collider Programme) (Valencia)
🏢 FORESEE
📍 Valencia